Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT05910775
Other study ID # 2000034829
Secondary ID 2UL1TR001863-06
Status Recruiting
Phase N/A
First received
Last updated
Start date May 3, 2024
Est. completion date July 2025

Study information

Verified date May 2024
Source Yale University
Contact Sina Nikayin, MD
Phone 203-688-9719
Email sina.nikayin@yale.edu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The investigators aim to examine the magnitude of non-specific effects in the treatment of depressive episodes with esketamine, by providing patients in the intervention group with a pretreatment presentation and post-treatment follow up session, to assess whether nonspecific effects can be used effectively to improve the effectiveness of treatment with esketamine.


Description:

Primary Objective: To determine whether a positive presentation before first treatment improves expectation of improvement from treatment in patients receiving esketamine for a depressive episode within 24 hours after the first treatment. Secondary Objectives: To determine whether a post-treatment follow up session to provide encouragement and reassurance improves expectation of improvement from treatment in patients receiving esketamine for a depressive episode within 24 hours after the first treatment. To determine whether a positive presentation results in an improved response from treatment in patients receiving esketamine for a depressive episode as measured by MADRS score within 24 hours after the first treatment. To determine whether a positive presentation before first treatment, combined with a posttreatment follow up session after first treatment, result in an improved response from treatment in patients receiving esketamine for a depressive episode as measured by MADRS score by the end of the acute course of esketamine treatment.


Recruitment information / eligibility

Status Recruiting
Enrollment 34
Est. completion date July 2025
Est. primary completion date July 2025
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Participants must be either male or female and at least 18 years old - Deemed clinically appropriate to receive esketamine by a Yale Interventional Psychiatry physician. - Written consent for the study procedures - Ability and willingness, in the investigator's judgement, to comply with the study schedule, treatment plan, and other trial requirements for the duration of the study. Exclusion Criteria: - Hearing or visual impairment to the degree that would interfere with ability to view the presentation - Difficulty in understanding spoken or written English - Unable to provide informed consent - Dementia or other cognitive disorder or intellectual disability that would impair the subject's ability to understand the presentation (per investigator judgment) - Any other medical or psychiatric comorbidity that the investigator judges would put the participant at additional undue risk due to study participation or would impair subject's ability to participate in the study. - Previous Esketamine or ketamine treatment - Unable to give informed consent - Was previously enrolled/randomized into the trial

Study Design


Related Conditions & MeSH terms


Intervention

Behavioral:
Pre and Post Treatment Presentations
A short presentation provided to the participants within 72 hours prior to the first treatment of the acute course. The presentation will emphasize the effectiveness of the treatment, and provide notable encouragement and reassurance. The intervention group will additionally receive a follow up session within 24 hours after the first treatment to provide encouragement and reassurance

Locations

Country Name City State
United States Yale Psychiatry Hospital Interventional Psychiatry Services (IPS) unit New Haven Connecticut

Sponsors (2)

Lead Sponsor Collaborator
Yale University National Center for Advancing Translational Sciences (NCATS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Group difference in change in question 6 score on Treatment Credibility and Expectancy Scale (CEQ-6) Participants' expectations will be assessed by the change in the group score of item 6 of the CEQ-6 at baseline and after the presentation (before treatment 1). Item 6 is scored from 0% (not at all) to 100% (very much). Higher scores indicates expectations have been met. baseline and after presentation (before treatment 1), up to 30 days
Secondary Group difference in change in Montgomery-Åsberg Depression Rating Scale (MADRS) score MADRS score will be used to assess whether a positive presentation results in an improved response from treatment in participants receiving esketamine for a depressive episode within 24 hours after the first treatment. MADRS is a ten-item diagnostic questionnaire used to measure the severity of depressive episodes. Each item is rated on a 0-6 scale, resulting in a maximum total score of 60 points, with higher scores indicative of greater depressive symptomology. baseline and within 24 hours post treatment 1
See also
  Status Clinical Trial Phase
Completed NCT04469322 - Pharmacogenetic Implementation Trial in Veterans With Treatment Refractory Depression N/A
Recruiting NCT02481245 - BezafibrateTreatment for Bipolar Depression: A Proof of Concept Study Phase 2
Completed NCT03449979 - Single Session of tACS in a Depressive Episode N/A
Recruiting NCT05708222 - Sleep Signal Analysis for Current Major Depressive Episode (SAMDE)
Completed NCT01879111 - Increasing the Efficiency of Depression-screening Using Patient-targeted Feedback N/A
Unknown status NCT01212848 - Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation Phase 3
Not yet recruiting NCT05547711 - Prediction and Validation of Unipolar Depression With Psychosocial-somatic Markers in a Naturalistic Cohort Recruited in an Outpatient Setting N/A
Completed NCT04239521 - The Epidemiology, Management, and the Associated Burden of Related Conditions in Alopecia Areata
Completed NCT03288714 - Adaptive Design Study of NEST sTMS in Subjects With Major Depressive Disorder N/A
Completed NCT03899168 - Confirmation Bias Towards Treatments of Depressive Disorders in Social Tagging N/A
Terminated NCT03537547 - Combinatorial Pharmacogenomics Testing in Treatment-Naïve Major Depressive Disorder Phase 4
Terminated NCT04383509 - Electroconvulsive Treatment Followed by Cognitive Control Training N/A
Completed NCT05683028 - RCT for Electroconvulsive Treatment Followed by Cognitive Control Training N/A
Enrolling by invitation NCT05701345 - Study of Virtual Reality-based Medical Device for Patients With Depressive Disorder N/A
Recruiting NCT04123301 - Theta-Burst Stimulation in Major Depressive Episodes With Mixed Characteristics. N/A
Completed NCT05686408 - Study to Evaluate TNX-601 ER Monotherapy Versus Placebo in Patients With Major Depressive Disorder (MDD) Phase 2
Completed NCT03543410 - A Clinical Study to Test the Effectiveness of an Investigational Drug to Treat People That Have Major Depressive Episodes When They Have Bipolar 1 Depression Phase 2
Completed NCT04953338 - Mental Health Associations With Vitiligo
Recruiting NCT06152705 - Comparing the Efficacy of fMRI-Guided vs. Standard iTBS in Treating Depression N/A
Completed NCT05462652 - Self-guided Treatment for Adolescents Navigating Depression N/A